Lars Fruergaard Jørgensen, Novo Nordisk CEO (Photographer: Christopher Goodney/Bloomberg via Getty Images)

Most dos­es of No­vo Nordisk's Ozem­pic are re­moved from FDA drug short­age list af­ter sup­ply is­sues

No­vo Nordisk’s type 2 di­a­betes treat­ment Ozem­pic, which is al­so used off-la­bel for weight loss, is back in stock fol­low­ing a months-long short­age, ac­cord­ing to the FDA’s drug short­ages list.

The FDA up­dat­ed its web­site on Fri­day to show that Ozem­pic’s 0.25 mg, 0.5 mg and 1 mg dos­es are now avail­able across the US. The 0.25 mg and 0.5 mg dos­es suf­fered lim­it­ed sup­ply for the last few months, ac­cord­ing to a No­vo Nordisk spokesper­son. How­ev­er, the 2 mg dose has “lim­it­ed avail­abil­i­ty and may not ful­ly meet de­mand un­til the end of this month,” the com­pa­ny told End­points News on Mon­day.

Endpoints News

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters